Oculogenex: Detailed Company Information & Corporate Profile

Contact top employees from Oculogenex

Summary

The company currently specializes in the Biotechnology area. To connect with Oculogenex employee register on SignalHire.

Oculogenex Websiteoculogenex.com
Social Links
linkedIn
Phone Number562-726-4424
Industries
Oculogenex Headquarters address2250 W Whittier Blvd, La Habra, California, 90631 US
Company Size1-10 employees
SpecialtiesGene Therapy, Biotechnology, Biopharmaceuticals, Macular Degeneration, Retinal Disease, Ophthalmology, Retina, Drug Delivery
Founded2020

Competitors

Name
Founded
Type
Employees
Revenue
Funding
2017Privately
Held
25 - 100 4.5M $9.4M
2018Privately
Held
1 - 25 158.2M $534M
2020- 10-50 15.1M $-

Workforce Turnover

Corporate Tenure Analytics

arrow

Oculogenex's workforce includes employees across a wide range of tenure levels.

50% have been with the company for 3 to 4 years50% have been with the company for 5 to 7 years

Former Employees: Role Changes

Role at Former Company
Role at New Company
Contact top employees from Oculogenex
Ram Ramkumar
Ram RamkumarChief Operating Officer
Phone (1)
+1-***-***-4919
Unlock contacts

Oculogenex Corporate Information: FAQ

Oculogenex operates in the Biotech industries. More details can be found on the official website: oculogenex.com.
The headquarters of Oculogenex are located in La Habra, United States.
You can contact Oculogenex by phone at 562-726-4424.
Oculogenex currently employs 1-10 people.
Well-known competitors of Oculogenex include Navrogen, Day One Biopharmaceuticals and Comanche Biopharma.

Data Privacy

GDPR Icon

GDPR COMPLIANT

SignalHire complies with the General Data Protection Regulation (GDPR). SignalHire follows GDPR requirements, including but not limited to rights of data subjects to access, correct, or delete their personal information and supports the right to be forgotten.

CCPA Icon

CCPA COMPLIANT

SignalHire is CCPA-compliant and provides California residents the right to know, access, opt out, and request deletion of their personal data.

BACK TO TOP